Next generation of weight management medications: implications for diabetes and CVD risk.

Wharton, S; Serodio, K J

Wharton, S; Serodio, K J.

Affiliation

Wharton S; Weight Management and Diabetes Management, The Wharton Medical Clinic, 414 Victoria Ave N Suite 14, Hamilton, ON, L8L 5G8, Canada, wharton.sean@gmail.com.

Curr Cardiol Rep ; 17(5): 35, 2015 May.

Article in En | MEDLINE | ID: mdl-25894803

Subject(s)

Anti-Obesity Agents/classification; Anti-Obesity Agents/therapeutic use; Obesity/complications; Obesity/drug therapy; Weight Loss/drug effects; Cardiovascular Diseases/complications; Diabetes Mellitus, Type 2/complications; Humans; Risk Factors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Weight Loss / Anti-Obesity Agents / Obesity Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Curr Cardiol Rep Journal subject: CARDIOLOGIA Year: 2015 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google